Regenerative Organ Tissue Replacement Procedures- Brings Elimination of Need for Liver Transplants
Updated: Jun 29
Since 2000, liver diseases have continually risen to become one of the leading causes of death and illness. The World Health Organization (WHO), reports that about 46% of global diseases and 59% of the world mortality is because of chronic liver diseases and almost 35 million people in the world die of chronic diseases annually.
In the United States, there are over 17,000 patients on the liver transplant waiting list, there are but only enough donated livers to perform about 5,000 transplants per year. As a result, more than 1,700 patients die each year while on liver waiting lists. The median national waiting time in 2006 was 321 days.
Each year in the United States, about 21,000 men and 8,000 women get liver cancer, and about 16,000 men and 6,000 women die from the disease.
These facts make clear the need for a liver repair and in-body liver health rejuvenation procedure. There are not enough available, compatible livers for all the transplant requests and there are risks of rejection to every transplant that is performed.
The answer is- find an effective solution that regenerates the patient’s existing liver, in-place (“the in the body solution”), and in creating this fix, use the patient’s DNA to assure an exact match.
An excellent solution is now being offered. It is scheduled to be available for general delivery to liver patients within 18 to 24 months. The solution Company, BCM Industries, is currently continuing trials and in parallel is designing and constructing a volume production manufacturing facilities to initially service the liver replacement needs of many thousands of liver patients. To learn how and follow the progress, review the information provided at the BCM Industries and the RTH Foundation websites.
Chronic liver disease occurs throughout the world irrespective of age, sex, region or race. Cirrhosis is an end result of a variety of liver diseases characterized by fibrosis and architectural distortion of the liver with the formation of regenerative nodules and can have varied clinical manifestations and complications. According to WHO, about 46% of global diseases and 59% of the mortality is because of chronic diseases and almost 35 million people in the world die of chronic diseases.
Liver disease rates are steadily increasing. Chronic liver disease mortality continues to rise in the United States driven largely by a spike in nonalcoholic fatty liver disease (NAFLD). About 100 million individuals in the United States are estimated to have nonalcoholic fatty liver disease.
Among chronic liver disease–related deaths, the most common diagnostic etiology was NAFLD (34.7%), followed by alcoholic liver disease (28.8%) and chronic Hepatitis C (21.1%). Nonalcoholic fatty liver disease and its subtype nonalcoholic steatohepatitis affect approximately 30% and 5%, respectively, of the US population.
More than 5 million people are living with chronic Hepatitis B or chronic Hepatitis C in the United States. Approximately 20% to 25% cases of liver cirrhosis are from the Hepatitis C virus (HCV) infection. An estimated 1.4 million people in the United States are living with chronic hepatitis B infection.
The Regents of The University of California. https://www.ucsfhealth.org/education/living-donor-liver-transplant-the-facts
BMJ Publishing Group Ltd- Mortality due to cirrhosis and liver cancer in the United States, 1999-2016; https://www.bmj.com/content/362/bmj.k2817
World Gastroenterology Organization. https://www.worldgastroenterology.org/publications/e-wgn/e-wgn-expert-point-of-view-articlescollection/global-burden-of-liver-disease-a-true-burden-on-health-sciences-and-economies
American Liver Foundation https://liverfoundation.org/liver-disease-statistics/#alcohol-related-liver-disease-and-cirrhosis
Frontline Medical Communications Inc. https://www.mdedge.com/jcomjournal/article/184170/hepatology/us-death-rates-chronic-liver-disease-continue-rise
European Association for the Study of the Liver. https://www.journal-of-hepatology.eu/article/S0168-8278(19)30140-0/fulltext